Product Description
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Clovis Oncology
Company Location: BOULDER CO 80301
Company CEO: Patrick J. Mahaffy
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT02705339 | P2 |
Withdrawn |
Non-Small-Cell Lung Cancer |
2019-11-01 |
|
| NSCLC | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2019-07-30 |
|
| CO-1686-008 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2018-07-03 |
|
| TIGER-3 | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2018-03-29 |